Joshua Boger, Ph.D.

22 Liberty Dr PH 2F
Boston, MA 02210-1333
Joshua.Boger@gmail.com



Chair of the Board
Cervomed, Inc. (NASDAQ: CRVO)
Boston, MA 02116

Founder and CEO (Former)
Vertex Pharmaceuticals
(NASDAQ: VRTX)

Senior Advisor, Founding Exec. Chair
Alkeus Pharmaceuticals Inc
Cambridge, MA 02138

Director – mOm Incubators
Nottingham, England NG5 1 AP

Dr. Joshua Boger is Chair of the Board of Cervomed, a public biotech company (NASDAQ: CRVO) developing an oral therapy for Lewey body dementia and related neurological conditions and is a Senior Advisor and former Chair of the Board (and its Founding Executive Chair) of Alkeus Pharmaceuticals, a private biotech company, bringing through development a novel, oral therapy for intractable eye diseases. He also serves as an Investor Director of the London-based company, mOm Incubators Ltd, a neonatal healthcare care device company bringing the world's first suitcase-sized, high-tech, portable, baby incubator to hospitals and clinics around the world and for emergency use in disaster and war-torn areas. He was the Founder of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and retired as Vertex's Chief Executive Officer in May 2009, after over 20-years with the company. He continued to serve on the Vertex Board and Chaired its Science & Technology Committee, stepping off the board in June 2017, after more than 28 years. Prior to founding Vertex in 1989, Dr. Boger was Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, N.J., where he headed both the Departments of Biophysical Chemistry and Medicinal Chemistry of Immunology & Inflammation. During his ten years at Merck, Dr. Boger developed an international reputation in the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs.

Dr. Boger holds a bachelor-of-arts degree in Chemistry and Philosophy from Wesleyan University (Connecticut) and a master's and doctorate degrees in Chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn in Strasbourg, France. He is the author of over 50 scientific publications, holds 32 issued U.S. patents in pharmaceutical discovery and development, and has delivered over 125 invited lectures, in the United States, in Europe and in Asia, on various aspects of drug discovery and development. He was named one of forty "Technology Pioneers" worldwide for the 2003 World Economic Forum in Davos, Switzerland. He was named in 2009 to the Biotech Hall of Fame, received in 2012 the Chemical Heritage Foundation & BIO 13th Annual Biotechnology Heritage Award, was given an All-Stars Lifetime Achievement Award in 2015 from the Boston Business Journal, and, in 2018, received the Othmer Gold medal - their highest award - from the Science History Institute and a Doctor of Science honorary degree from Wesleyan University. He received the Distinguished Community Leadership Award in 2009 from the Jewish Alliance for Law & Social Action (JALSA), the Heroes in Health Award in 2012 from the Visiting Nurse Association of Boston, the Massachusetts Women's Political Caucus' Good Guys Award in 2015, the Fenway Health/AIDS Walk Boston Bette Byrnes Award in 2022, the Colonel Francis T. Colby Award from the Boston Museum of Science in 2023, Boston Business Journal's Power 50 Movement Makers in 2024, and Boston Arts Academy Honors in Visual Arts in 2024. In 2025 he received MassChallenge's Deval Patrick Commonwealth Innovation Award and a Doctor of Science honorary degree from Princeton University.

Dr. Boger is Chair of the Board of the Celebrity Series (Boston's premier performing arts presenter). He serves on several additional non-profit Boards, including the Board of Fellows of Harvard Medical School (where he is Chair Emeritus), the Science Advisory Council of WGBH (public broadcasting's leading station, Boston), and the Young Achievers Foundation Ghana. He served for over ten years as Vice-Chair of Boston's Museum of Science and continues as a Trustee Emeritus. He is a former member of the Harvard Board of Overseers, served on the MIT Corporation Visiting Committees for the Departments of Biology and for the Institute for Medical Engineering & Science (IMES). He co-founded and served for fifteen years as Vice-Chair of the Alliance for Business leadership (a Boston-based, non-partisan coalition of progressive business leaders), served on the boards of the Hastings Center for Bioethics (the world's oldest independent bioethics research institute, Garrison, NY) and the Whitehead Institute (Cambridge, MA), was a founding Director of the Massachusetts Life Sciences Center (the quasi-public overseer of a $1Billion state-funded development initiative), was a Trustee and Chair of the Board of Wesleyan University (Middletown, CT), chaired the Harvard Medical School's $750M *Campaign for Harvard Medicine,* was founding Chair of the Board of MassChallenge (the world's largest startup business incubator), and, while a member of the Board of the ACLU of Massachusetts Foundation he co-founded their ongoing *Technology for Liberty* and *Justice for All* Projects.

Alkeus Pharmaceuticals, Inc. (www.alkeuspharma.com) Alkeus is a development-stage biotechnology company developing a novel, oral therapy, gildeuretinol (ALK-001), which blocks an undesirable chemical side reaction of Vitamin A that may lead to vision loss and blindness in a number of eye diseases. The company has presented Phase II results from a blinded and placebo-controlled clinical trial of gildeuretinol in Stargardts disease, a monogenic, recessive disease that is the largest such cause of blindness in children and young adults. The company has begun a Phase III study ("Northstar") directed towards approval of gildeuretinol for this indication. In addition, Alkeus has completed a Phase II clinical trial in geographic atrophy, the most severe form of dry-eye adult macular degeneration (AMD. That trial showed a slower decline in vision-related quality of life and in functional reading scores compared to placebo, demonstrating a meaningful functional benefit in this leading cause of vision loss and blindness in older adults.

CervoMed (www.cervomed.com) is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Cervomed is developing an oral therapy, neflamapimod, that inhibits the enzyme p38 alpha. The company believes that if neflamapimod is given in the early stages of neurological disease, it may reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. CervoMed has presented results from a Phase 2b clinical study in patients with dementia with Lewy bodies (DLB), showing, in a six month extension portion of the study, significant positive improvements in cognitive function and in motor function. The company is preparing to begin later this year an FDA-endorsed Phase III study for DLB, a disease without any effective treatment. Additionally, the company believes the same drug may be effective in mechanistically-related diseases such as prefrontal dementia and Alzheimer's disease and may improve the process of recovery from ischemic strokes.

mOm Incubators Ltd. (www.momincubators.com) is a medical device company focusing on neonatal healthcare. It's flagship product, the mOm Essential Incubator, is a cost-effective, compact, and lightweight infant incubator, offering a safe, medical-grade thermoregulated environment for newborns. Approved in the UK and Europe with a "CE mark" (Conformité Européene), the incubator has been sold to hospitals in UK and will soon be introduced across Continental Europe. It has been deployed in resource-challenged healthcare systems in Haiti, Kenya, Tanzania, and Nepal, and has been rushed into emergency use situations in Ukraine and, in early 2025, into Gaza. In Ukraine alone it has been credited with helping to save the lives of over 3,000 babies. The device is approved by the US FDA under 510(k) as equivalent to the standard incubators, and introduction in the US market is underway. Deployment in the Democratic Republic of Congo and in Sudan is expected by mid-2026.

Vertex Pharmaceuticals Incorporated (www.vrtx.com) Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For.

Personal: He is married to Amy Boger, M.D., F.A.A.P., a professional ceramic artist, and they have three sons. Dr. Boger is an expert scuba diver & a professional underwater photographer, a competition-licensed formula racecar driver and a lifelong Boston Red Sox fan. He served as one of the [secret] judges for the weekly New Yorker cartoon contest in the Bob Mankoff era. On 26 April 2007 he flew onboard the historic zero-gravity flight with Professor Stephen Hawking.

An amateur photographer for more than 60 years, including technical photography for over 50 years, Dr. Boger began to explore underwater photography in the late 1990's, intrigued by the technical challenges as well as the possibilities to explore an often alien-looking aesthetic world. He made the transition to digital underwater photography as soon as equipment was available, allowing more rapid feedback for the problem of changing color balance with depth, a consequence of varying spectral absorption with depth of sunlight through water. This led to his first professional one-man gallery show of his underwater photography in 2014. Since then, he has mounted twelve additional professional photography exhibits; previous one-man shows include galleries in Lowell (MA), Waltham (MA), Cambridge (MA), Boston (MA), and at the Waterman Gallery of the Rhode Island School of Design. He has a permanent exhibit of more than twenty photographs at Wesleyan University (CT). His photographs hang in homes and businesses around the world, including in Boston, New York, San Francisco, Palm Beach, Shanghai, London, Paris and Montreux (Switzerland). His latest show, "Soul Windows", goes above water to look closely at animal eyes across Asia and Africa, and ran in Boston for most of October 2024. Along with his wife, Amy, a ceramic artist, he was honored in late October 2024 for Visual Arts by the Boston Arts Academy at their annual Honors gala.